Ondine Biomedical Inc.

DB:VF5 Stock Report

Market Cap: €41.6m

Ondine Biomedical Valuation

Is VF5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VF5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VF5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VF5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VF5?

Key metric: As VF5 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VF5. This is calculated by dividing VF5's market cap by their current revenue.
What is VF5's PS Ratio?
PS Ratio38.2x
SalesCA$1.63m
Market CapCA$62.41m

Price to Sales Ratio vs Peers

How does VF5's PS Ratio compare to its peers?

The above table shows the PS ratio for VF5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
GME Geratherm Medical
1x1.9%€18.4m
NN6 NanoRepro
4.7xn/a€16.8m
AAQ1 aap Implantate
1.3xn/a€15.6m
PUS PULSION Medical Systems
3.7xn/a€133.6m
VF5 Ondine Biomedical
38.2x66.0%€34.5m

Price-To-Sales vs Peers: VF5 is expensive based on its Price-To-Sales Ratio (38.2x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does VF5's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x4.2%US$841.99m
PHH2 Paul Hartmann
0.3xn/aUS$822.71m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
VF5 38.2xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VF5 is expensive based on its Price-To-Sales Ratio (38.2x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is VF5's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VF5 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio38.2x
Fair PS Ratio10.9x

Price-To-Sales vs Fair Ratio: VF5 is expensive based on its Price-To-Sales Ratio (38.2x) compared to the estimated Fair Price-To-Sales Ratio (10.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VF5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.077
€0.72
+832.1%
8.3%€0.78€0.66n/a2
Dec ’25€0.069
€0.72
+954.6%
8.3%€0.78€0.66n/a2
Nov ’25€0.074
€0.68
+818.2%
13.0%€0.77€0.59n/a2
Oct ’25€0.058
€0.66
+1,048.5%
18.2%€0.78€0.54n/a2
Sep ’25€0.059
€0.65
+1,007.3%
18.2%€0.77€0.53n/a2
Aug ’25€0.073
€0.65
+787.3%
18.2%€0.77€0.53n/a2
Jul ’25€0.067
€0.65
+874.1%
18.2%€0.77€0.53n/a2
Jun ’25€0.067
€0.64
+863.2%
18.2%€0.76€0.52n/a2
May ’25€0.04
€0.64
+1,521.7%
18.2%€0.76€0.52n/a2
Apr ’25€0.089
€0.67
+653.3%
13.0%€0.76€0.58n/a2
Jan ’25€0.076
€0.67
+780.0%
13.0%€0.76€0.58n/a2
Dec ’24€0.07
€0.67
+848.7%
13.0%€0.76€0.58€0.0692
Nov ’24€0.12
€0.67
+462.0%
13.0%€0.76€0.58€0.0742
Oct ’24€0.082
€0.67
+715.6%
13.0%€0.76€0.58€0.0582
Sep ’24€0.081
€0.67
+730.8%
13.0%€0.76€0.58€0.0592
Aug ’24€0.15
€0.67
+337.1%
13.0%€0.76€0.58€0.0732
Jul ’24€0.12
€0.66
+446.4%
13.0%€0.75€0.57€0.0672
Jun ’24€0.16
€0.66
+323.8%
13.0%€0.75€0.57€0.0672
May ’24€0.19
€0.71
+272.6%
4.0%€0.74€0.68€0.042
Apr ’24€0.15
€0.71
+362.1%
4.0%€0.74€0.68€0.0892
Mar ’24€0.17
€1.08
+521.7%
48.4%€1.82€0.68€0.0933
Feb ’24€0.20
€1.08
+435.5%
48.4%€1.82€0.68€0.0993
Jan ’24€0.21
€1.08
+420.1%
48.4%€1.82€0.68€0.0763
Dec ’23€0.26
€1.08
+316.0%
48.4%€1.82€0.68€0.073

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 19:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ondine Biomedical Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SimmsArden Partners Plc.
David DeanCormark Securities Inc.
Charles WestonRBC Capital Markets